1117 Role of Second Generation Contrast-Enhanced Ultrasonography (CEUS) in Diagnosis of Pancreatic Lesions Sperandeo Marco, Unit of Internal Medicine “Casa Sollievo della Sofferenza”; San Giovanni Rotondo, Italy Piattelli Maria Luisa, Unit of Internal Medicine “Casa Sollievo della Sofferenza”; San Giovanni Rotondo, Italy Siena Domenico, Unit of Endoscopy “Casa Sollievo della Sofferenza”; San Giovanni Rotondo, Italy Ippolito Antonio, Unit of Gastroenterology-”Casa Sollievo della Sofferenza”; San Giovanni Rotondo, Italy Andriulli Angelo, Unit of Gastroenterology-”Casa Sollievo della Sofferenza”; San Giovanni Rotondo, Italy Annese Vito, Unit of Endoscopy “Casa Sollievo della Sofferenza”; San Giovanni Rotondo, Italy Terracciano Fulvia, Unit of Endoscopy, Italy The development of CEUS has contributed to improve the diagnosis of pancreatic lesions. However, only few controlled studies are available. We aimed to prospectively evaluate the role of CEUS in characterization of pancreatic lesions.58 patients (38 male, median age 73 yrs) with 63 histologically proven pancreatic lesions detect- able at the US were investigated. The final diagnosis were: 18 adenocarcinoma, 5 insulinomas, 8 mass forming pancreatitis (MFP), 6 intraductal papillary mucinous tumors [IPMT], 13 pseudocystis, 8 serous cystadenoma [SCA] and 5 mucinous cystadenoma [MCA]. After standard US, 2-4 mL of Sonovue i.v. was administered. The CEUS findings were compared with those obtained by computed tomography (CT) or magnetic resonance (MRI). The histological diagnosis in all cases was obtained either from biopsy or surgical specimens. Results: Based on CEUS findings, solid lesions showing hypovascular pattern were diagnosed as carcinomas, those with hypervascular pattern as neuroendocrin tumors, and the hysovascular ones as MFP. All lesions fit these US criteria according to final diagnosis.CT or MRI findings in all cases were also confirmed at the final diagnosis. Con- cerning the cystic lesions, all except one were non vascular, even when a corpuscular content was found at basal US (sensitivity 90%). In all cases of SCA and MCA with intralesional septis, CEUS demonstrated a vascular enhancement. In contrast, in the absence of intralesional features within cystic lesions differential diagnosis could not be achieved (sensitivity 65%). Conclusions: Our data, although preliminary, demonstrate that the study of the pancreas is a new and promising application of CEUS. 1118 Value of the Contrast-Enhanced Ultrasound in the Diagnosis of Venous Thrombosis of Pancreatic Transplantation A ´ ngeles Garcı ´a-Criado, Clinic Hospital of Barcelona, Spain Rosa Marı ´a Gilabert, Clinic Hospital of Barcelona, Spain Luis Bianchi, Clinic Hospital of Barcelona, Spain Marı ´a Isabel Real, Clinic Hospital of Barcelona, Spain Marı ´a Jose ´ Ricart, Clinic Hospital of Barcelona, Spain Laureano Ferna ´ndez-Cruz, Clinic Hospital of Barcelona, Spain Objective: To determine the value of contrast-enhanced ultrasound (CEUS) in the diagnosis of acute venous pancreas graft thrombosis, which accounts for the majority of graft loss in the early postoperative period after pancreas transplantation Patients and Methods: One hundred consecutive pancreatic grafts (14 isolated pancreas and 86 pancreas-kidney transplantations) performed from january-2005 to septembre-2008 were included in this prospective study. Vascular graft permeability was assessed with Colour Doppler Ultrasound (CDUS). The CEUS study was carried out when CDUS did not detect flow in the splenic or mesenteric veins, but grey scale ultrasound (US) did not demon- strate the presence of thrombi. Results: US detected 18 thrombosis. In other 20 grafts CEUS was performed because no flow was detected by CDUS and no thrombus was demonstrated by US: in 13, the splenic and mesenteric veins were permeable but with low flow; in 7 CEUS detected vein throm- bosis (splenic, 4; mesenteric, 2; both, 1). Two grafts had small distal thrombi and no arteriographic studies were performed. In the 5 remaining the arteriography confirmed the diagnosis. Conclusion: CEUS can determine the extension of venous thrombosis and exclude its presence in situations of low venous flow. CEUS increases the diagnostic performance of CDUS avoiding the arte- riograpy in non-conclusive CDUS studies. 1119 Comparision of the Hepatic Transit Time (HTT) of First and Second Generation Contrast Agents in Patients with Liver Metastases an in Healthy Controls Thomas Haendl, Dept. Medicinie 1 University of Erlangen- Nuremberg, Germany Deike Strobel, Dept. Medicinie 1 University of Erlangen-Nuremberg, Germany Markus Frieser, Dept. Medicinie 1 University of Erlangen- Nuremberg, Germany Eckhart G Hahn, Dept. Medicinie 1 University of Erlangen- Nuremberg, Germany Daniel Neureiter, Dept. Pathology University of Salzburg, Austria Thomas Bernatik, Dept. Medicinie 1 University of Erlangen- Nuremberg, Germany Introduction: Liver metastases lead to a shortening of the HTT of an echo enhancer. Our study examined whether the analysis of the HTT with currently available contrast agents is useful to discriminate be- tween patients with and without liver metastases. Material and Methods: We compared the arterio-venous HTT of Levovist™, Sonovue™ und Luminity™ in 20 patients with proven liver metastases and in 15 healthy controls. An acuson sequoia™ ultrasound system was used. The hepatic artery and a branch of a hepatic vein were visualized in an intercostal section. The HTT results from the difference of the arrival time of the microbubbles in the hepatic artery and a hepatic vein. Results: Using Levovist™ six patients and three controls had to be excluded form further analysis, because the arrival time was undetect- able. The HTT in healthy controls: SonoVue™ 9.27s (SD  2.41s), Luminity™ 9.2s (SD  2.34s) and Levovsit™ 14.75s (SD  2.53s). In patients with liver metastases: SonoVue™ 6.28s (SD  2.41s), Lumi- nity™ 6.33s (SD  1.37s) Levovist™ 9.89s (SD  1.04s). A cut off value of 8s for SonoVue™ and Luminity™ had sensitivity to exclude liver metastases of 75% and 80%. Conclusion: The mean HTT of all contrast agents were shorter in patients. Levovist™ showed a significant longer HTT in patients and controls. Levovist™ is not useful for a HTT measurement since a continuous monitoring is often not possible. The HTT could be a useful tool to exclude liver metastases. The transit time depends on the contrast agent. S130 Ultrasound in Medicine and Biology Volume 35, Number 8S, 2009